MedPath

Dorzagliatin

Generic Name
Dorzagliatin
Drug Type
Small Molecule
Chemical Formula
C22H27ClN4O5
CAS Number
1191995-00-2
Unique Ingredient Identifier
X59W6980E8
Background

Dorzagliatin is under investigation in clinical trial NCT03173391 (Long-term Efficacy and Safety of HMS5552 in T2DM).

Clinical Trials
Related News

DDI Study Between Dorzagliatin and Rifampicin

Phase 1
Completed
Conditions
Drug Interaction
Interventions
First Posted Date
2019-09-06
Last Posted Date
2019-09-06
Lead Sponsor
Hua Medicine Limited
Target Recruit Count
15
Registration Number
NCT04080609
Locations
🇨🇳

Central Hospital of Xuhui District, Shanghai, Shanghai, China

DDI Study to Investigate the Impact of Itraconazole on the Pharmacokinetics of Dorzagliatin

Phase 1
Completed
Conditions
Drug Interaction
Interventions
First Posted Date
2019-09-06
Last Posted Date
2019-09-06
Lead Sponsor
Hua Medicine Limited
Target Recruit Count
18
Registration Number
NCT04080596
Locations
🇨🇳

The 2nd Hospital of Jilin University, Changchun, Jilin, China

Drug Interaction Study Between Dorzagliatin and Empagliflozin

Phase 1
Completed
Conditions
Patients
Interventions
First Posted Date
2019-01-02
Last Posted Date
2025-03-24
Lead Sponsor
Hua Medicine Limited
Target Recruit Count
16
Registration Number
NCT03790787
Locations
🇺🇸

Frontage Clinical Services Inc., Hackensack, New Jersey, United States

Drug Interaction Study Between Dorzagliatin and Sitagliptin

Phase 1
Completed
Conditions
Patients
Interventions
First Posted Date
2019-01-02
Last Posted Date
2023-02-28
Lead Sponsor
Hua Medicine Limited
Target Recruit Count
15
Registration Number
NCT03790839
Locations
🇺🇸

Frontage Clinical Services Inc., Hackensack, New Jersey, United States

Long-term Efficacy and Safety of HMS5552 in T2DM Subjects

Phase 3
Completed
Conditions
Diabetes Mellitus, Type 2
Interventions
Drug: Placebo
First Posted Date
2017-06-01
Last Posted Date
2021-08-26
Lead Sponsor
Hua Medicine Limited
Target Recruit Count
463
Registration Number
NCT03173391
Locations
🇨🇳

Hua Medicine Limited, Shanghai, Shanghai, China

Human Mass Balance Study of HMS5552 in Healthy Subjects

Phase 1
Completed
Conditions
Healthy Subject
Interventions
First Posted Date
2017-05-18
Last Posted Date
2018-12-31
Lead Sponsor
Hua Medicine Limited
Target Recruit Count
6
Registration Number
NCT03158506
Locations
🇺🇸

Celerion, Lincoln, Nebraska, United States

Long-term Efficacy and Safety of HMS5552 add-on to Metformin in T2DM Subjects

Phase 3
Completed
Conditions
Diabetes Mellitus, Type 2
Interventions
Drug: Placebo
First Posted Date
2017-05-04
Last Posted Date
2021-08-26
Lead Sponsor
Hua Medicine Limited
Target Recruit Count
767
Registration Number
NCT03141073
Locations
🇨🇳

Hua Medicine Limited, Shanghai, China

Drug-Drug Interaction Study of Glucokinase Activator HMS5552 and Metformin in T2DM

Phase 1
Completed
Conditions
Type 2 Diabetes Mellitus
Interventions
First Posted Date
2015-11-05
Last Posted Date
2016-02-17
Lead Sponsor
Hua Medicine Limited
Target Recruit Count
12
Registration Number
NCT02597400
Locations
🇺🇸

Frontage Clinical Services Inc., Hackensack, New Jersey, United States

A Multi-center 12-week Study of HMS5552 in T2DM

Phase 2
Completed
Conditions
Diabetes Mellitus, Type 2
Interventions
Other: Placebo
First Posted Date
2015-09-28
Last Posted Date
2020-03-10
Lead Sponsor
Hua Medicine Limited
Target Recruit Count
258
Registration Number
NCT02561338
Locations
🇨🇳

Nanjing Drum Tower Hospital The Affiliated Hospital of Nanjing University Medical School, Nanjing, Jiangsu, China

Beta Cell Function and Related Pharmacodynamics of HMS5552 in T2DM Patients

Phase 1
Completed
Conditions
Type 2 Diabetes
Interventions
First Posted Date
2015-03-12
Last Posted Date
2015-05-14
Lead Sponsor
Hua Medicine Limited
Target Recruit Count
24
Registration Number
NCT02386982
Locations
🇨🇳

The 1st Betuhune Hospital of Jilin University, Changchun, China

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy